Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2

Abstract excerpt

OBJECTIVE: The hallmark oncogene MYC drives the progression of most tumours, but direct inhibition of MYC by a small-molecule drug has not reached clinical testing. MYC is a transcription factor that depends on several binding partners to function. We therefore explored the possibility of targeting MYC via its interactome in pancreatic ductal adenocarcinoma (PDAC). DESIGN: To identify the most suitable targets...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Pancreatic and Hepatic Oncology Research
• Share to Phagocytosis and Immune Regulation
• Share to Ubiquitin and proteasome pathways